Get the Stockscreener App
30.24
7.65%
2.15
After Hours:
30.06
-0.18
-0.60%
Hims Hers Health Inc stock is traded at $30.24, with a volume of 16.12M.
It is up +7.65% in the last 24 hours and down -10.90% over the past month.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
See More
Previous Close:
$28.09
Open:
$28.73
24h Volume:
16.12M
Relative Volume:
0.81
Market Cap:
$7.00B
Revenue:
$2.35B
Net Income/Loss:
$128.37M
P/E Ratio:
57.92
EPS:
0.5221
Net Cash Flow:
$57.42M
1W Performance:
-7.52%
1M Performance:
-10.90%
6M Performance:
+1.89%
1Y Performance:
-47.55%
1-Day Range:
$28.15
$30.32
1-Week Range:
$27.93
$35.85
52-Week Range:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Name
Hims Hers Health Inc
Sector
Phone
415-851-0195
Address
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
30.24 | 6.50B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
17.44 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.94 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.08 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.92 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
527.94 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Initiated | JP Morgan | Overweight |
| Mar-10-26 | Upgrade | BofA Securities | Underperform → Neutral |
| Mar-10-26 | Upgrade | Citigroup | Sell → Neutral |
| Mar-09-26 | Upgrade | Needham | Hold → Buy |
| Feb-24-26 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-12-26 | Initiated | Evercore ISI | In-line |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-21-25 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-23-25 | Downgrade | Needham | Buy → Hold |
| Jun-04-25 | Reiterated | Needham | Buy |
| Apr-29-25 | Downgrade | TD Cowen | Buy → Hold |
| Feb-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-25 | Downgrade | Citigroup | Neutral → Sell |
| Jan-07-25 | Initiated | BTIG Research | Buy |
| Dec-17-24 | Initiated | Morgan Stanley | Overweight |
| Nov-14-24 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-22-24 | Initiated | Needham | Buy |
| Aug-09-24 | Downgrade | Imperial Capital | Outperform → In-line |
| May-22-24 | Downgrade | Citigroup | Buy → Neutral |
| Apr-16-24 | Downgrade | Jefferies | Buy → Hold |
| Apr-10-24 | Initiated | Canaccord Genuity | Buy |
| Feb-28-24 | Upgrade | Imperial Capital | In-line → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-07-23 | Initiated | Imperial Capital | In-line |
| Jul-28-23 | Initiated | TD Cowen | Outperform |
| Apr-11-23 | Initiated | Robert W. Baird | Neutral |
| Feb-09-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-08-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-08-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-17-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Sep-07-22 | Initiated | Truist | Hold |
| Jul-15-22 | Initiated | SVB Leerink | Underperform |
| Apr-14-22 | Initiated | Guggenheim | Buy |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | Deutsche Bank | Hold |
| Dec-02-21 | Initiated | Jefferies | Hold |
| Nov-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jul-06-21 | Initiated | BofA Securities | Neutral |
| May-20-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Apr-21-21 | Initiated | Truist | Hold |
| Mar-09-21 | Initiated | Credit Suisse | Neutral |
| Mar-02-21 | Upgrade | Citigroup | Neutral → Buy |
| Feb-17-21 | Initiated | Citigroup | Neutral |
| Feb-12-21 | Initiated | Piper Sandler | Neutral |
| Feb-08-21 | Initiated | Tigress Financial | Buy |
View All
Hims Hers Health Inc Stock (HIMS) Latest News
HIMS Stock Rises Overnight: Retail Traders Bet On Peptides Upside After FDA Panel Backs 6 Of 7 Compounds - Stocktwits
Hims & Hers Health Stock (HIMS) Opinions on FDA Peptide Decisions - Quiver Quantitative
Why Is HIMS Stock Rallying 13% Today? - Stocktwits
A Hims cofounder fired his entire marketing team for AI. Now his 24/7 online vet service is growing 20% a month - Yahoo Finance
FDA Panel Narrowly Backs Four Peptides — Hims & Hers Stock in the Spotlight - Yahoo Finance
Hims & Hers Health (HIMS) Shares Fall After FDA Panel's Negative Vote on Emideltide - GuruFocus
HIMS Maintains by Truist Securities -- Price Target Raised to $2 - GuruFocus
Hims & Hers Health, Repligen, West Pharmaceutical Services, and 10x Genomics Stocks Trade Down, What You Need To Know - Yahoo Finance
HIMS Stock Sinks as FDA Gives Hims & Hers Peptide the Cold Shoulder - Yahoo Finance
Hims & Hers (HIMS) Stock Looks Cheap On Cash Flow But Pricey After A 313% Run - Yahoo Finance
HIMS Stock Dives Sharply as Uninsured Patients Raise Concerns while FDA Process Remains Uncertain - FXLeaders
HIMS Stock Falls Over 10% Amid Market Fluctuations - GuruFocus
Hims & Hers down as FDA advisors snub first peptide (HIMS:NYSE) - Seeking Alpha
Is Today’s Dip a Buying Opportunity for Hims & Hers Health (HIMS) Stock? - TipRanks
Hims & Hers Health Slides as Traders Fade Peptide Rally - Quiver Quantitative
Hims & Hers: Peptide Ruling A Positive, Operational Good Sense Makes 'Buy' Case (Upgrade) - Seeking Alpha
HIMS Stock Climbs Overnight As FDA Advisory Panel Backs 4 Peptides — ‘Pharma Bro’ Martin Shkreli Goes Short - Stocktwits
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now? - Yahoo Finance
Peptide catalyst lift for Hims & Hers (NYSE:HIMS) limited by FDA review timetable - TechStock²
Hims & Hers Health: Favorable Decision on Peptides Lifts Investor Appetite but Uncertainty Very High - Morningstar
Telehealth firms urge FDA to legalize peptides, with guardrails - Crain's New York
What Shapes Hims & Hers Health (NYSE:HIMS) Russell 2000 View? - Kalkine Media
FDA Peptide Shift And Leadership Change Could Be A Game Changer For Hims & Hers Health (HIMS) - simplywall.st
Is It Too Late to Buy Hims & Hers Health Inc (HIMS) After 3.4% R - GuruFocus
Hims & Hers Health, Inc. Stock 12‑Month Price Target Raised to $30.38, Implies 4% Downside - TradingView
Hims & Hers Health (HIMS) Gains On FDA Panel News, Is The Valuation Gap Still Wide? - Yahoo Finance
HIMS Maintained by Citigroup -- Price Target Raised to $35.00 - GuruFocus
What the FDA’s Peptide Decision Means for Hims & Hers’ Long-Term Telehealth Strategy - Barron's
Hims & Hers Stock Jumps 13% After FDA Panel Backs BPC-157 for Compounding - finance.biggo.com
Hims & Hers Health, Inc. stock Analysis: FDA Catalyst Impacts Neutral Regime - The Cryptonomist
FDA advisers back first of seven peptides under review for looser rules - Reuters
Hims & Hers Health (NYSE:HIMS) rises as FDA BPC-157 decision turns market attention to revenue per subscriber - TechStock²
HIMS Shares Surge Over 10% Following FDA Panel Decision - GuruFocus
HIMS Stock Surges Following FDA Advisory Panel Decision - GuruFocus
Hims & Hers gains as FDA panel endorses peptide BPC-157 (HIMS) - Seeking Alpha
Hims & Hers Health shares jump on FDA’s push to expand BPC-157 access - Investing.com Canada
Hims & Hers stock jumps after FDA panel backs BPC-157 access - Investing.com Canada
Hims & Hers stands to gain if the FDA loosens restrictions on peptides - Reuters
Telehealth Firms Urge FDA to Legalize Peptides, With Guardrails - Bloomberg.com
$Hims & Hers Health (HIMS.US)$ - Moomoo
Hims & Hers Health Inc (HIMS) Shares Fall 3.2% -- What GF Score of 83 Tells Investors - GuruFocus
Hims & Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
HIMS Stock Slips Overnight: Hims & Hers Bulks Up Debt Raise To $350M For Eucalyptus Buyout, AI Push - Stocktwits
The FDA Is About to Weigh in on the Great Peptide Debate - inc.com
Form 144 Hims & Hers Health For: 22 July By Investing.com - Investing.com Canada
Hims & Hers Health, Inc. SEC Filing (Jul 22, 2026) - Stock Titan
HIMS Sees Surge in App Downloads Amid Peptide Opportunity - GuruFocus
HIMS Stock Snaps 3-Day Losing Streak: FDA Adds 8 New Peptide Voters Deemed ‘More Qualified And Less Conflicted’ - Stocktwits
$Hims & Hers Health (HIMS.US)$ 24th July is the key peptide hearing? - Moomoo
Lobbying Update: $290,000 of HIMS & HERS HEALTH INC. lobbying was just disclosed - Quiver Quantitative
Hims & Hers stock analysis: growth story meets credibility crisis ahead of FDA catalyst - Investing.com Canada
Hims Hers Health Inc Stock (HIMS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.30%
2.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):